Group 1 - The core viewpoint of the article highlights that Kehua Bio (002022.SZ) is leveraging its strong technical foundation in in vitro diagnostics to establish a solid base for the home self-testing market [1] - The company plans to focus on developing home testing products in respiratory, digestive, and reproductive health areas, aiming to enrich its product offerings [1] - Kehua Bio intends to integrate its products with digital devices and software to create a personal health management ecosystem [1] Group 2 - The company employs a dual sales model of direct sales and distribution, and currently does not have stores on e-commerce platforms [1]

Core Viewpoint - The company is leveraging its strong technical foundation in in vitro diagnostics to establish a solid base for the home testing market, focusing on respiratory, digestive, and reproductive health products [1] Group 1: Company Strategy - The company plans to continuously enrich its product offerings in the home testing sector [1] - The company is integrating digital devices and software to build a personal health management ecosystem [1] - The company employs a dual sales model of direct sales and distribution, and has not yet opened stores on e-commerce platforms [1]